LoginSignup
immagine del profilo
Aktien Stammtisch
@Aktien_Stammtisch
1Mes·

$ABBV (+1,12%)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (+0,75%) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commenti
Sebastian B.@Baisse-Jumper
1Mes
Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
•
9
•
immagine del profilo
Iwas M.@SSIT
1Mes
If AbbVie goes down even further, I might spontaneously get in today ^^
•
3
•
Visualizza tutti 4 ulteriori risposte
immagine del profilo
Thomas@WolfofNersingen
1Mes
Am in
•
2
•
immagine del profilo
Vertriebsliebhaber@Vertriebsliebhaber
1Mes
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
•
2
•
immagine del profilo
Saschko@WarrenamBuffet
1Mes
stupid :(
••
immagine del profilo
Stefan@Slucks87
1Mes
Gut :)
••
Proolix@Proolix
1Mes
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
••
Partecipa alla conversazione
IscrivitiAccesso